Triple therapy versus biologic therapy for Active Rheumatoid Arthritis a cost-effectiveness analysis

Annals of Internal Medicine

Volumn 167, Issue 1, 2017, Pages 8-16

  Bansback, Nick ^a   Phibbs, Ciaran ^b   Sun, Huiying ^c   O'Dell, James R ^d   Brophy, Mary ^e,k   Keystone, Edward C ^f   Leatherman, Sarah ^g,k   Mikuls, Ted R ^d   Anis, Aslam H ^a   Ayoub, William ^d   Boire, Gilles ⁱ   Bykerk, Vivian ^j   Chow, Andrew ^k   Colburn, Keith ^l   Daikh, David ^m   Davis, John ⁿ   El Gabalawy, Hani ^o   Elliott, Jennifer ^p   Fanciullo, Joseph ^q   Gupta, Samardeep ^r   Hannagan, Keri ^s   Hausch, Raymond ^t   Holmberg, Erika ^s   Joseph, Amy ^u   Kazi, Salahuddin ^v   Kent, Peter ^w   Kerr, Gail ^x   Kolba, Karen ^y   Kwoh, C Kent ^z   Mahowald, Maren ^aa   Martin, Liam ^ab   Olenginski, Thomas ^d   Persselin, Jay ^ac   Peshimam, Mahfooz ^ad   Peterson, Lynne ^ae   Prete, Pamela ^af   Pugliese, David ^h   Reddy, Virginia ^v   Reimold, Andreas ^v   Rodrigues, Jude ^k   Schumacher, H Ralph ^ag   Thorne, J Carter ^ah   Valeriano Marcet, Joanne ^ai   Weaver, Cynthia ^k   Phibbs, Ciaran S ^k   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST PAUL S HOSPITAL   (Canada)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g Massachusetts Veterans Epidemiology and Research Information Center   (United States)

^h GEISINGER HEALTH SYSTEM   (United States)

ⁱ UNIVERSITÉ DE SHERBROOKE   (Canada)

^j HOSPITAL FOR SPECIAL SURGERY   (United States)

^k Mayo Clinic ^*  (United States)

^l LOMA LINDA UNIVERSITY   (United States)

^m VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁿ MAYO CLINIC   (United States)

^o UNIVERSITY OF MANITOBA   (Canada)

^p Rheumatology and Osteoporosis Services   (United States)

^q Avera Research Institute   (United States)

^r BRIGHAM AND WOMEN S HOSPITAL   (United States)

^s VA BOSTON HEALTHCARE SYSTEM   (United States)

^t Duluth Clinic   (United States)

^u VA St Louis Healthcare System   (United States)

^v UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^w PARK NICOLLET INSTITUTE   (United States)

^x VETERANS AFFAIRS MEDICAL CENTER   (United States)

^y Pacific Arthritis Center   (United States)

^z UNIVERSITY OF PITTSBURGH   (United States)

^aa VA MEDICAL CENTER   (United States)

^ab UNIVERSITY OF CALGARY   (Canada)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad UND School of Medicine & Health Sciences Southeast Campus   (United States)

^ae SANFORD RESEARCH   (United States)

^af UNIVERSITY OF CALIFORNIA   (United States)

^ag UNIVERSITY OF PENNSYLVANIA   (United States)

^ah ANIMAL HEALTH TRUST   (United Kingdom)

^ai UNIVERSITY OF SOUTH FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

ADULT; ARTICLE; BIOLOGICAL THERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; LIFE TABLE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HUMANS; LIFE TABLES; MALE; METHOTREXATE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 85020038137     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-0713     Document Type: Article

References (33)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-39. [PMID: 22473917] doi:10.1002/acr.21641
2. Drugs.com. Top 100 drugs for Q1 2013 by sales-U. S. pharmaceutical statistics. 2014. Accessed at www.drugs.com/stats/top100/2013/q1/sales on 29 September 2014.
3. Zhang J, Xie F, Delzell E, Chen L, Kilgore ML, Yun H, et al. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken). 2013;65:1743-51. [PMID: 23754804]
4. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum. 2008;58:939-46. [PMID: 18383356] doi:10.1002/art.23374
5. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374:459-66. [PMID: 19665644] doi:10.1016/S0140-6736 (09) 60944-2
6. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al; TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64:2824-35. [PMID: 22508468] doi:10.1002/art.34498
7. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al; CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369:307-18. [PMID: 23755969] doi:10.1056/NEJMoa1303006
8. Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016;353:i1777. [PMID: 27102806] doi:10.1136/bmj.i1777
9. Curtis JR, Zhang J, Xie F, Beukelman T, Chen L, Fernandes J, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2014;66:1604-11. [PMID: 24942466] doi:10.1002/acr.22383
10. Ng B, Chu A, Khan MM. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. BMJ Open. 2013;3. [PMID: 23562815] doi:10.1136/bmjopen-2012-002468
11. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al; ISPOR Task Force on Good Research Practices-Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9-17. [PMID: 12535234]
12. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8:521-33. [PMID: 16176491]
13. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8. [PMID: 7818570]
14. Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med. 2009;151:612-21. [PMID: 19884622] doi:10.7326/0003-4819-151-9-200911030-00006
15. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res. 1992;5:119-29. [PMID: 1457486]
16. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 2006;54:2784-92. [PMID: 16947781]
17. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009;181:787-96. [PMID: 19884297] doi:10.1503/cmaj.091391
18. Michaud K, Wallenstein G, Wolfe F. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18, 485 patients. Arthritis Care Res (Hoboken). 2011;63:366-72. [PMID: 21080449] doi:10.1002/acr.20405
19. Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis. 2010;69:1058-64. [PMID: 19717399] doi:10.1136/ard.2009.114652
20. Arias E. United States life tables, 2009. Natl Vital Stat Rep. 2014;62:1-63. [PMID: 24393483]
21. American College of Rheumatology. National Medicare fee schedule. Accessed at www.rheumatology.org/Practice-Quality/Administrative-Support/Medicare/Medicare-Fee-Schedule on 29 September 2014.
22. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203-20. [PMID: 15725977]
23. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ. 1997;6:243-52. [PMID: 9226142]
24. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500. [PMID: 10977389]
25. Pedro S, Wolfe F, Jalal H, Michaud K. Discontinuation rates in patients with RA of triple disease modifying antirheumatic therapy [abstract]. Arthritis Rheum. 2013;65:1055.
26. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9. [PMID: 15262104]
27. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334:1287-91. [PMID: 8609945]
28. Chang RW, Pellisier JM, Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA. 1996;275:858-65. [PMID: 8596224]
29. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and diseasespecific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478-87. [PMID: 10902749]
30. Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Ann Rheum Dis. 2015;74:1094-101. [PMID: 24737786] doi:10.1136/annrheumdis-2013-205060
31. Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ. 2015;350:h1046. [PMID: 25769495] doi:10.1136/bmj.h1046
32. Jalal H, O'Dell JR, Bridges SL Jr, Cofield S, Curtis JR, Mikuls TR, et al. Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1751-7. [PMID: 27015606] doi:10.1002/acr.22895
33. van Vollenhoven RF, Chatzidionysiou K. Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA? Nat Rev Rheumatol. 2013;9:510-2. [PMID: 23897440] doi:10.1038/nrrheum.2013.118